GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud
Executive Summary
GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?
You may also be interested in...
Ranbaxy Fraud Settlement Emphasizes Guilty Pleas, Downplays Exclusion
Although pharmaceutical company settlements in the millions of dollars now seem customary, a guilty plea to seven felonies could signal aggressive government pursuit of manufacturing and data integrity concerns.
Are GMP Violations The “Next Hot Thing” In False Claims Act Litigation?
Former prosecutors say there are cases pending under seal, but it is uncertain whether the government will intervene. They note the difficulty in proving the allegations and say FDA’s regulatory regime may be a better route for handling GMP issues.
Are GMP Violations The “Next Hot Thing” In False Claims Act Litigation?
Former prosecutors say there are cases pending under seal, but it is uncertain whether the government will intervene. They note the difficulty in proving the allegations and say FDA’s regulatory regime may be a better route for handling GMP issues.